<SEC-DOCUMENT>0001193125-14-199919.txt : 20140515
<SEC-HEADER>0001193125-14-199919.hdr.sgml : 20140515
<ACCEPTANCE-DATETIME>20140515061433
ACCESSION NUMBER:		0001193125-14-199919
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140515
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140515
DATE AS OF CHANGE:		20140515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		14843682

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d728525d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): May&nbsp;15</B>, <B>2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21392</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2, Ireland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;15, 2014, Corsicanto Limited, a private limited company incorporated under
the laws of Ireland (&#147;Corsicanto&#148;) and a wholly owned subsidiary of Amarin Corporation plc (the &#147;Company&#148;), and the Company entered into separate, privately negotiated exchange agreements with certain holders of its outstanding
3.50% Exchangeable Senior Notes due 2032 issued on January&nbsp;9, 2012 (the &#147;Existing Notes&#148;) pursuant to which Corsicanto will exchange $118.734 million in aggregate principal amount of the Existing Notes for $118.734 million in
aggregate principal amount of new 3.50%&nbsp;May 2014 Exchangeable Senior Notes due 2032 (the &#147;New Notes&#148;) (the &#147;Exchange Transactions&#148;). Following the closing of the Exchange Transactions, $31.266 million in aggregate principal
amount of the Existing Notes will remain outstanding with terms unchanged. The Exchange Transactions are expected to close on May&nbsp;20, 2014, subject to customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Notes will be issued pursuant to an Indenture (the &#147;Indenture&#148;), to be entered into by the Company, Corsicanto and Wilmington Trust,
National Association, as trustee (the &#147;Trustee&#148;). The New Notes will be the senior unsecured obligations of Corsicanto and will be guaranteed by the Company. The New Notes will bear interest at a rate of 3.50%&nbsp;per annum from, and
including, January&nbsp;15, 2014, payable semi-annually in arrears on January&nbsp;15 and July&nbsp;15 of each year, beginning on July&nbsp;15, 2014. The New Notes will mature on January&nbsp;15, 2032, unless earlier repurchased or redeemed by
Corsicanto or exchanged by the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time after the issuance of the New Notes and prior to the close of business on the second business day
immediately preceding January&nbsp;15, 2032, holders may exchange their New Notes at their option. If prior to January&nbsp;15, 2018, a make-whole fundamental change (as defined in the Indenture) occurs or the Company elects to redeem the New Notes
in connection with certain changes in tax law, in each case as described in the Indenture, and a holder elects to exchange its New Notes in connection with such make-whole fundamental change or election, as the case may be, such holder may be
entitled to an increase in the exchange rate as described in the Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange rate will initially be 384.6154 ADSs per $1,000 principal amount
of the New Notes (equivalent to an initial exchange price of approximately $2.60 per ADS (the &#147;Exchange Price&#148;)), subject to adjustment in certain circumstances. The initial exchange price for the New Notes represents an approximately 71%
exchange premium over the last reported sale price of the ADSs on The NASDAQ Global Market on May&nbsp;14, 2014, which was $1.52 per ADS. Upon exchange, the New Notes are to be settled in ADSs. The exchange rate is subject to adjustment from time to
time upon the occurrence of certain events, including, but not limited to, the payment of cash dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to January&nbsp;19, 2018, Corsicanto may
not redeem the New Notes at its option other than in connection with certain changes in the tax law of a relevant taxing jurisdiction that results in additional amounts (as defined in the Indenture) becoming due with respect to payments and/or
deliveries on the New Notes. On or after January&nbsp;19, 2018, Corsicanto may redeem for cash all or a portion of the New Notes at a redemption price of 100% of the aggregate principal amount of the New Notes to be redeemed, plus accrued and unpaid
interest to, but not including, the redemption date. If a Fundamental Change (as defined in the Indenture) occurs, holders may require Corsicanto to repurchase all or part of their New Notes for cash at a Fundamental Change repurchase price equal to
100% of the aggregate principal amount of the New Notes to be repurchased, plus accrued and unpaid interest to, but not including, the Fundamental Change repurchase date. In addition, holders of the New Notes may require Corsicanto to repurchase all
or any portion of the New Notes on each of January&nbsp;19, 2019,&nbsp;January&nbsp;19, 2024 and January&nbsp;19, 2029 for cash at a price equal to 100% of the aggregate principal amount of the New Notes to be repurchased, plus accrued and unpaid
interest to, but not including, the repurchase date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corsicanto may elect at its option to cause all or any portion of the New Notes to be mandatorily
exchanged in whole or in part at any time prior to the close of business on the business day preceding January&nbsp;15, 2032 if the Daily VWAP (as defined in the Indenture) equals or exceeds 110% of the Exchange Price then in effect for at least 20
VWAP Trading Days (as defined in the Indenture) in any 30 VWAP Trading Day period. Corsicanto may only exercise its optional exchange rights upon satisfaction of specified equity conditions, including that the ADSs issuable upon exchange of the New
Notes be eligible for resale without registration by non-affiliates and listed on The NASDAQ Global Market, its related exchanges or the New York Stock Exchange. If Corsicanto elects to exercise its optional exchange rights on or prior to
January&nbsp;15, 2018, each holder whose New Notes are exchanged will upon exchange receive a specified number of additional ADSs as set forth in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Indenture will contain customary terms and covenants and events of default. If an event of default (other than certain events of bankruptcy, insolvency or
reorganization involving Corsicanto) occurs and is continuing, the Trustee by notice to Corsicanto, or the holders of at least 25% in principal amount of the outstanding New Notes by notice to Corsicanto and the Trustee, may declare 100% of the
principal of and accrued and unpaid interest, if any, on all of the New Notes to be due and payable. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and
payable immediately. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving Corsicanto, 100% of the principal of and accrued and unpaid interest, if any, on all of the New Notes will become due and payable
automatically. Notwithstanding the foregoing, the Indenture will provide that, to the extent Corsicanto elects and for up to 360 days, the sole remedy for an event of default relating to certain failures by Corsicanto or the Company, as the case may
be, to comply with certain reporting covenants in the Indenture consists exclusively of the right to receive additional interest on the New Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corsicanto has agreed to use its commercially reasonable efforts to procure the listing of the New Notes on the Global Exchange Market operated under the
supervision of the Irish Stock Exchange (or on another recognized stock exchange for the purposes of Section&nbsp;64 of the Taxes Consolidation Act 1997 of Ireland and within the meaning of Section&nbsp;1005 ITA 2007 of the United Kingdom) prior to
July&nbsp;15, 2014, which will be the first interest payment date for the New Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the New Notes and the Indenture do not
purport to be complete and are qualified in their entirety by reference to the Indenture (which will include the form of the New Note). A copy of the Indenture (which will include the form of the New Note) is expected to be attached as an exhibit to
a Current Report on Form 8-K to be filed by the Company following the closing of the Exchange Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;15, 2014, the Company issued a
press release with respect to the transactions described above. A copy of this press release is furnished as Exhibit 99.1 hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company offered the
New Notes to certain holders of the Existing Notes in reliance on the exemption from registration provided by Section&nbsp;4(a)(2) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). The offer and sale of the New Notes to
certain holders of the Existing Notes did not involve a public offering, the solicitation of offers for the New Notes was not done by any form of general solicitation or general advertising, and offers for the New Notes were only solicited from
persons believed to be institutional &#147;accredited investors&#148; within the meaning of Rule 501(a)(1), (2), (3)&nbsp;or (7)&nbsp;of Regulation D promulgated under the Securities Act or &#147;qualified institutional buyers&#148; within the
meaning of Rule 144A promulgated under the Securities Act. The New Notes and any ADSs that may be issued upon exchange of the New Notes will not be registered under the Securities Act, and may not be offered or sold in the United States absent
registration under the Securities Act or an applicable exemption from registration requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form 8-K does not constitute an
offer to sell, or a solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering would be unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form
8-K contains forward-looking statements concerning the Company&#146;s expectations, anticipations, intentions, beliefs or strategies regarding the proposed Exchange Transactions, the principal amount of the Existing Notes subject to the exchange and
the resulting allocation of principal between the Existing Notes and New Notes, and the applicable conversion price of the New Notes. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties.
Among the factors that could cause actual results to differ materially from those described or projected herein are the following: financial market conditions, actions by our exchange counterparties prior to the closing of the Exchange Transactions,
our ability to continue to commercialize and increase market acceptance of Vascepa&reg; (icosapent ethyl), our continued interactions with the FDA, the inherent uncertainties of maintaining intellectual property rights and protections, our ability
to successfully operate under current and future collaboration arrangements, and the results of our current and future clinical trials. A further list and description of these risks, uncertainties and other risks associated with an investment in the
Company can be found in Company&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May 15, 2014.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;15, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">John Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit&nbsp;Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May 15, 2014.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d728525dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g728525ex99_1pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Announces Private Exchange Transactions </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Outstanding Senior Exchangeable Notes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>First put option date moved from 2017 to 2019 for exchanged notes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland&#150; May&nbsp;15, 2014 &#150; Amarin Corporation plc (Nasdaq: AMRN) (&#147;Amarin&#148;), announced today that it and
its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the &#147;Issuer&#148;), have entered into separate, privately negotiated exchange agreements with certain holders of its outstanding
3.50% Exchangeable Senior Notes due 2032 issued on January&nbsp;9, 2012 (the &#147;2012 Notes&#148;) pursuant to which the Issuer will exchange $118.734 million in aggregate principal amount of the 2012 Notes for $118.734 million in aggregate
principal amount of new 3.50%&nbsp;May 2014 Exchangeable Senior Notes due 2032 (the &#147;2014 Notes&#148;). Following the closing of these transactions, $31.266 million in aggregate principal amount of the 2012 Notes will remain outstanding with
terms unchanged. The 2014 Notes will be exchangeable into American Depositary Shares of Amarin (&#147;ADSs&#148;) at the option of the holders at an initial exchange rate of 384.6154 ADSs per $1,000 principal amount of 2014 Notes (equivalent to an
initial exchange price of approximately $2.60 per ADS), subject to adjustment in certain circumstances. The exchange is expected to close on May&nbsp;20, 2014, subject to customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2014 Notes will accrue interest at an annual rate of 3.50% from, and including, January&nbsp;15, 2014. Interest on the 2014 Notes will be payable
semiannually in arrears on January&nbsp;15 and July&nbsp;15 of each year, beginning July&nbsp;15, 2014. The 2014 Notes will mature on January&nbsp;15, 2032, unless previously repurchased, redeemed or exchanged in accordance with their terms prior to
such date. The Issuer&#146;s obligations under the 2014 Notes will be fully and unconditionally guaranteed by Amarin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the 2014 Notes will have
the option to require the Issuer to purchase any outstanding 2014 Notes on each of January&nbsp;19, 2019,&nbsp;January&nbsp;19, 2024 and January&nbsp;19, 2029 at a purchase price equal to 100% of the principal amount thereof, plus accrued and unpaid
interest thereon. The Issuer will have the right to redeem the 2014 Notes on or after January&nbsp;19, 2018 at a redemption price equal to 100% of the principal amount thereof, plus accrued but unpaid interest thereon. The 2014 Notes will also
provide the Issuer with the option to exchange the 2014 Notes in whole or in part, prior to maturity, into the underlying ADSs, provided the trading price of one ADS of Amarin equals or exceeds $2.86 (or 110% of the then applicable exchange price)
for the required measurement period. If the Issuer exercises the exchange option on or before January&nbsp;15, 2018, in certain circumstances, the applicable exchange rate will be increased in accordance with a make-whole table included in the
indenture that will govern the 2014 Notes. In addition, the exchange rate will be increased in certain circumstances for exchanges in connection with certain fundamental changes in accordance with the same make-whole table. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and
shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The 2014 Notes and the ADSs issuable upon exchange of the 2014 Notes will not be registered under the Securities Act of
1933, as amended (the &#147;Securities Act&#148;), or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration
requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc
is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential
therapeutic benefits of polyunsaturated fatty acids. Vascepa&reg; (icosapent ethyl), Amarin&#146;s first FDA approved product, is a patented, ultra-pure omega-3 fatty acid product comprising not less than 96% EPA and is available by prescription.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
contains forward-looking statements concerning Amarin&#146;s expectations, anticipations, intentions, beliefs or strategies regarding the proposed exchange transactions, the principal amount of 2012 Notes subject to the exchange and the resulting
allocation of principal between the 2012 Notes and 2014 Notes, and the applicable conversion price of the 2014 Notes. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors
that could cause actual results to differ materially from those described or projected herein are the following: financial market conditions, actions by our exchange counterparties prior to the closing of the exchange transaction, our ability to
continue to commercialize and increase market acceptance of Vascepa, our continued interactions with the FDA, the inherent uncertainties of maintaining intellectual property rights and protections, our ability to successfully operate under current
and future collaboration arrangements, and the results of our current and future clinical trials. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s
filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as
of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Farrell </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908)&nbsp;719-1315 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investor.relations@amarincorp.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g728525ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g728525ex99_1pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^(,6$E#
M0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`
M,0``86-S<$U31E0`````245#('-21T(```````````````$``/;6``$`````
MTRU(4"`@````````````````````````````````````````````````````
M```````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````4
M8FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D``
M```49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P``
M`]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E12
M0P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`
M````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V
M,3DV-BTR+C$`````````````````````````````````````````````````
M`````````````````%A96B````````#S40`!`````1;,6%E:(```````````
M``````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4`
M`!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M````````````````````````````````````````````````````````````
M9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````````
M`&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````````
M``!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@````
M``!,"58`4````%<?YVUE87,``````````0````````````````````````*/
M`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`
M*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5
M`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!
M#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A
M`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"
M9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/
M`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$
M<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'
M/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*
MW`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS
M#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_
MHC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#
M`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`00$L`P$1``(1`0,1`?_$`-T`
M``(#``$%`0`````````````*"`D+!0$#!`8'`@$``@,``P$`````````````
M``<%!@@"`P0!$```!@$#`@,%`P4'#@P'```!`@,$!08'``@)$1(A$PHQX6*B
M%$$B%6$R(Q8747&Q,[=X.8%2<H*R0W,DM;:7&#@:\)&AP=%"U39V5W<9LS1T
M5=8G*!$``0($`P0%!0H*"`4%`````0(#`!$$!2$Q!D%181)Q@2(3!Y&AT3(4
M\+'A4F*2LB,5-<%"<H+"TC-S%C9#4Y.S)'0F%_&BXM,T8X-$9$7_V@`,`P$`
M`A$#$0`_`'\SJ]@].WKX=?;T^T?R#^YH@C\>?\'S>[1!!Y_P?-[M$$'G_#\W
MNT01QTS/Q%<B)2?L$G&P4#!Q[R6FIN8?MHR(B(J/04=/Y.4D7IT6C"/8M4C*
M++*G*FF0HF,(`&N3:5.K#38)>49!($R9X8#;'!:TMH*U&2`)S.`PXQ4#L7YN
M-J?(!NZW#;5L*B^-^Q^&83^.<C24@@E$9^AH]XK$Y$FJ1"JM&S]C$U"779`U
M45455E6#H7A4T$R"4;9>]&W6PVIBYUHEWI(4C:V<T!1F?6'S3@8@[=J&CN5<
M[1,?B>JJ?K@>L92PELSYACAB(N/\_P"'YO=JHC$`[XG\=L'G_!\WNT00>?\`
M!\WNT00>?\'S>[1!!Y_P?-[M$$'G_!\WNT00>?\`!\WNT00>?\'S>[1!!Y_P
M?-[M$$'G_!\WNT00>?\`!\WNT00>?\'S>[1!!Y_P?-[M$$'G_!\WNT00>?\`
M!\WNT00>?\'S>[1!!Y_P?-[M$$'G_!\WNT00>?\`!\WNT00>?\'S>[1!!Y_P
M?-[M$$'G_!\WNT00>?\`!\WNT00>?\'S>[1!!Y_P?-[M$$'G_!\WNT00>?\`
M!\WNT00>?\'S>[1!!Y_P?-[M$$'G_!\WNT00>?\`!\WNT01^_-^YW]OV].G7
M_GZ:(([2_P">']B'\(Z(([.B"#1!`'MT2!P.4'1G")OJV-UN[BE9)Q;M0CK]
M!U7:EE7&25_<U6E/EV5UR#/0MA<1,W'Y;4%?ZU6H1KY-LK%,D"I1ST_>=<%U
MVW1)V^%%KM-0PY=%H*[DTYR@JD4I!$QR"6!EF<3T0MM<5U>PM%(E032J3.0G
M.>,Y^3#TXA2[9[NAR#LOW,X<W.XR64"U8CN+"P?AA5U&[:S5U3N8VVFR1DQ#
MOB[96G3IBL`]>T%@.'WB%$&M=[537>VNVU\#E=01/<H>JKI!QXD"*):ZY=NK
M4539ERJ$]QQV].1X$QL48$S;0=R6%<6Y\Q;*IS6/LN4B`O56?)G3.<L=.L4G
M0L'H)F.5"4B'1E&CM'KW(ND%$S=#%'61JVC?M]6Y0U(_Q#2RD]1P/6,1O&,/
MVF?;J6$/M&:%IYO+LZLNJ/K>O+'?!H@@T00:((-$$&B"#1!!H@@T00:((-$$
M&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"
M.]_>?[;1!`O^>']B'\(Z(([.B"#1!'&3<W#UF$F++89)G#5^O14C.SLQ(+%;
ML(F&B&:TA*2;YP<0(@S8,FYU5#F$`*0HB/LUR0A;B@VV"5J,@!F2<`/+'%:D
MH05K,D`$D[@,X0&:;,,C>HDM_*-R$@YL$7"TMD&'^/:!<++M(V:E,8*(6%I#
MO&Y4Q;N6<Y46OT[DI1!-.=MJBXB)FG33V^V*?0#5NL$AWBR%U)P,@K"8W24<
M)[$2VPM'+<YJ=RKKU3`0)-C>1B$Y?%`GGVE=,*`/6+V,>/8V39.HV3C7;F.D
MHU\BHW>Q\@R7.U?,'C94I5&[MDZ2.DH0P`)#E$!\0TW0YWK?>(Y2@R.!\DN$
ML87:T%MPH6)$8'TX[\X>)])9R(&71O\`QO9)FNX[0LWF+;<J^<=5#-#&(XRK
MCEEY@"(@T6,6P,D2CX$5D1Z`!`TDO%2P#F1J&D!(,DNB4I;$'R]DGHAEZ&NW
M.@VQTXB93Z.O/.<P3MAX,=)>&,,A'31!%=>]SE,VC<>U@IU;W+3.2H-[>JY*
M6J#>4[$=]R#"IQ$/()QCY27FZK#R$;#.2.E`$J+A0BAD_O@';XZG;/INZ7UM
M;E`$%*%R,UI2>H*SB,N-VH[7R^U%0F-@GO\`1Z<X@$'JA.(`P`(9FR:8!`!`
M0P3DKH("'4!`0A_9TU/_`.VVJCBEILC]XGTQ#JUG8P9%:P1\@Q,+91S.;`>0
M/*LMA7;5E.?G\D1-0?WHU>M=`M-'/)5V*?Q\=*+PKFQ,&C>5=1RTH@=9!(QE
M2(G%3IV%,(1-YT??;%3)K+@VD4ZE2!2H*D3OECT91(V[4%MNKQ9I%DKE.121
ME%I^JP#/&)J#7V"(B;T]\^VSC\Q*RS7N@NKFF4B4ML51X<T5!2MIGIFRS#=Z
M];,(JO0:#F4>E081J[APH4GEMT4A,<0ZAUE;/9;A?JSV*VHYW@@J,R``!O)R
MCPW"XTEL9#]8KE;)D)9G/T153_O0?$#_`.<V3?\`01DK_L?5H_VTU8,"R@'B
MXF(/^,[%\=?S#$E=K'.7Q][S<OTW"&`K=EFSW:]N)AK`+2&#,E054%>"A9&>
MD225PDH-*OQ7EL8M4"^>N3O5`J8??,4!C+IHR^VBD565J6@TF4Y+258GXN<>
MZBU%;:]Y+-,I96K(%)'N]Z+?-56)R.H`(CT#J(_D_P"'LU\)D/<8(@YMVY&-
MH^ZO<!N$VT8+RBQO&3MM"T0GD%*/2*>NR2,B8S*2>T:P)+K-+;'U.?+^%2RZ
M'1-K(B5,!.4Y3FFKCI^ZVNA9N-<TINEJ!V#M&[F&PJ&(GF(CZ2Z45;4+I&%@
MOMYRR.^1VRVQ.,0Z:A1.4S$AQCIK[!%:>['EQV-[(<H*8CW+9!NU"M*=3B;K
M]8VP[E.UU,T#-+/V[-8+=4JI-0)7)%8Y0%D3+%41^[W@`&+UL-LTM>;S3&KM
MS:7&@KEESH2J?`*()B(KKY;K<\&*M2DN$3]51GU@2$1(?^I:X=627FI[EYR1
M'H(^3'X7R^JMX=O_`%5Z<W+][KX>/V:E4^'>KE>M3<HWE;?ZQCP*U=8@)]ZK
MYJO1'J(^IXXIUD5W<1;-P%C8M510<R,#MQR0]CVZO853L7=G8((I'$IP$"F$
M#=/'IT$!UWJ\-M3I(0XAE)E/%P8CR&!&K+0X@J;4L@;PF?G(CV.B^IBX?KM(
MI1CC<+:*(JHJ5`[B_P"'<E0C%JH80`2O7C.ORR#0"#^<8X@4.GMUTO>'>JVA
MS(80L?)6DD]$R(Y(U795*""X4J.]"CYQ,>>+?<$;F]N^Z"KA<]NV:\9YGK12
M)G<R6/+?#V48X5>[RT9EBP<JR,(Y-VC^B=HHJ>'YNJI76VOMCG=U[+K3LY26
M@I'49"?2)B)RFJZ>K'/3.-K`V`X]8V1]R_XOR>WQUX3,>L"$B<SGL&4>B6TS
MSQBF3<7SV\<^U3+-^POFRY9?J]TQO9%JI9#DP)D]_6QF$4$'`DAK2V@1A)QJ
MHDX**:S991-3Q[1'IJWV[1%_NE.W44@94VXGF';`,N(Q(,059J.V4+I9J5*"
MQN23[WHRCX1_O0?$#_YS9-_T$9*_['U(?[:ZK.(9;E^\3'B_C.Q?UB_F&.7A
M_4Q<4-B471KN1<V6!9J0%72,%MPRY,JMDQ_-.X3CJXZ,@0?L$W:`ZZU^'6J&
MS)2&0>+B1[\H[4:MLS@["U]:#\$>"[]3MQ'1ZYFLCE?+<<Z*`B+:0V^Y39."
M@!NT1%!U!)*@`&\/9X#KFGPWU0O%+;9Z'$X>[IC@K5]F1ZZEB7R#\,>,/J@^
M($`$?VRY.'H'7H&",E=?\CZY#PTU8?Z%O^T3'P:SL4\7%?,,70[<=R&%MVN&
MZ;GO;_>HK(>+[TQ%W"S\9YB*R#A$WDR,).1;DB4C`V*&=E,B\8NDTG#=4H@8
MO00$:;<+?66NL70UZ"W5-F12<1P(.1!X$Q8:6JIZQD5%,KF:5Q\W"/N&O''H
MBM#=]RZ[&-BN1RXJW*Y#N=+MPU.)NP_AN'\HVVOIUV:=R+)B[5M59JLG72*&
M<Q:I5$A<@HCT+W@7N+UL5ITI>[VP*BVMI6T5E.*T@S`!.!(.67X8BJV]VZWO
MBGJE*#A$\$J,^L`Q#!3U.7#Z4HB3.U]<'$0*FBWP9E119=0QNU-)`@UPOF**
MF$`*7VF$=3/^VVK1,EEL)`F27$2QZXC?XOL<\%K)W!)B<O\`[JVT?_4S_P!>
MSZ[+?^K]^M_ZE_7?L2R1^O/XQ^L'ZM^=^SK\"_6W\'_$?'ZWZ;Z?R/TO=V>.
MH7^&;G]K_8OU7MO)S>N.64I^ME$I]K4GL7M_:]GG++'W?APSPB8&0MPVW_%D
MZC6\H9TPYC:Q+QR$JA`7[)U(I\VM%N5G+=O))15BFXY^I'N'#15,BP)BF<Z1
MR@(B4W2'9H*^I1WE,RZXW.4TI41/=,`B<>QVJI&%<K[K:%RR4H`RZ#'S93?)
MLF1,<JN\;:LD9+N!0JFX3$A#)B3\X#E&W`8HEZ>/7V:]*;+>2,*2KEP:7+WH
MZOM*W#_Y#'ST^F.(7Y`MAK9(5E]Z^TU-(O:`G-N'Q/T`3"`!U`ML$?$1UV?8
M%]4,*2J_LU?JQUF[6L9U+'ST^F%]?42<L&'$MES/:[M(S[B/)^3MW=F1QA9)
MO&^4*C8X^A8J(LR/<5[+.04N[85I.Y+NVL,"CM5$@1[EZKU[41$+WH'2U;]K
MFYW2G>;8I4\R4J0I)6O)/*",>4]J6_EWQ6M2WRE-"*6D=;4X]@>50("-O#'C
M*8GC%IW'G=./78ULVP-MDJ>\S:*Y#&]+9(VN=9[@L/)EM&0Y<QYJ_P!G4.2W
M%,M^+VI\Y.D)NIB-@2)["`&JQ?V+_>KN_7N4E7S+7)([I>"1@E/JY@`=>,3%
MJ>M5OH44J'V.R,3SIQ4<5'/?@(21]1WL\QIBO=2UWD[9[/1\@;:MXDK8I9S9
M,76.!N%*J^X6NBW4RE5PG*L]D89LO9BO49U)N*H*?4+OB@4"H]`<_AS>'ZJV
MFT7%*D7.DD)+!2HMGU#RG'#U9YR`WF%UJ^W--50N%*4JI7IDE)!'-^,,,-L\
MS.?"*,-O&=\A;8,Y8JW"XJDC1>0<07:$O%;7[S%;NW$0Z*=["R(%\5H>Q1AE
MF#U,>H*-7"A1]NKS<Z"GNE`[052>9AQ!!X<?S3CT@16*&J<HJI%2V9*00>C'
MW3&T81L3;1]S6/=Y&VS#NYG%[HB]/R[2XRSMFGG)K.H"7.4S2RU24\L>B<O5
M;$V=1[DOAT6;F$/`0UD6ZVU^T7%VVU(^L:61/XPS"AP4"".F']0U;==2(JFO
M56/(=HZC,1(S4?'KCMKMFSU!5D];-WC-T0Z#EJ[02<MW"*Q1351616(=-1)4
MAA*8H@(&`>@Z^A2DGF22%"/BDI5ZP!Z8R8=^.T&:L>[_`)?+9B.N1,+2-GF?
MI^TV"BUZ,2:M(?&EYS#)4TLE`LF/:W8Q=2E9!D==!-/RT63A13[A$3:U+I^]
M(9M%I:JUDOU3"4A1.:@CFQ)S)E*><X2EVM:UUE6]3@!MIPS`&SG*<`-F(X"(
M<[&MUMNV0[M,&;HZ;]0N^Q/>&$O-PZ"RB(6BD/RJ1%[JBXD.3O2L-3?NVY0$
M>A5C$/[2`.IR_6IJ]6EZV/8!Q!D=RABE74<8B;37KMU>W4H.2A/B-QQ&8PQP
MQG&QEC3(M.R_CJBY6QY,MK#1,D5*OWBH3;0Y%$).NV>+;2\2[*)#'`AU&;HO
M>01[DS@)3=!`0UD.IIW:.H72/I*7VU%*AN4DR(^&'ZRZBH:2^V9MK2".@XB/
M=P_)XC^YKIF!G';[\9]/J&LI7CD*S_NEB,9S*A=K_$3B^&&^S*!5'4-:-Q66
M\A5.D2\&V4*=-O\`BK(CPS`JG506Z<"^$`_3:?/A_3,6&AIG*D#[5NCAY0=C
M24*5NP_ZANA9:J==NCSB63_A*1(GN*E+"3MQQR_(.^$^'`B"*XAU`024$!#V
M@($$0_>$--^<A@<(7C4BZD?B\P]^-F+C_K%;J&QG9["52`AJU$$VQX,>!&04
M8SBV7UDCC*LR,B\,W9HHIG=R+]RHNX5$!4664,<XB8PB..[T\\]>:IUY2E*[
M]S$DDX+('D&$:`M:$MVZGY``.Y1EQ&/EVQ+K47URB0A6/U4^\3-^VC:KAW'N
M#LX,L6NMPEQMM.R-7(%!=KE2V8ZC:XFZD7%:M;=V"U5JC=^X282YD4DG3W\1
M122<$("Z:C-\,;117.ZNO5['>(80%`GU4DDRF,B=V>1BFZSN-114*$4R^[4X
MHS&V4ACOEZ1L!$(L<>N]&\\?F[C$.Z"B@Z=DI$X#&\U5NN**5YQA/"G'WFGN
MNOZ,QY&(,95H8X""$BW;K>U/3OU#9F+[:GK>_CSIFE4@`E0]4C;@<]XPA9V>
MY.VRX(JD'L@CFXC:.L&7"<]@C8$Q5E&C9NQE0,PXSGFMGQ[DZI05XIL^S.4R
M$G7K)'-Y.-<="F-Y*X(.`*LD;[Z*I3$,`&*(!DJJIGJ*I<I*E)14-J*5`[Q@
M?^,/EAY%2RE]HS;6.8'@<?-'O^NB.V.`MD3$S]6L<+/14;-P\G!2[&2B9=BU
MDHV08N8]=-RR?,7B2S9VT<IB)5$SE,0Y1$!`0UV-*4VZ%MDI6E22"#(@[Q+(
MQP6E*TJ2H`CEVQB-SB::$[.H(ID210FY=%%),H$3212DG*:2290\"IID*```
M>``&MH,XM)G\4>]&<WP.^(V3$:%7H_V+938;N65623<?5;LY1NJDNDDLD*:.
M(<8"4.U0A@-W?4&Z@/4.G]76?O%A<[ZP!(2I4F?'G4,>.&<-30<C;'>;^M_1
M$6H<H/#=M2Y!,(WQJ7%=)H6XZ/K4U(XFS53J[%5NTLKBR9+O(:)MKN(;LPMM
M/FI!(C9\V?`N9-%45$#)+$(<*SIG5UTL5<@]XM=N*@%-*)(*20"4SR(S$I<8
MG+U8J.Y4JQW:457+-*@)3(G@99SXXC,1EP8.SQG?:7EB,RE@O(MMP]E>F2BK
M8LW5I%1BN9=@Z.A(0<_'CWQEB@UUD#I.6#Y%=JN3J4Y!UIFNH:&\4:F*QI+K
M#B9Y#(@2Y=QE*1$L<835/5U5MJ.=A2DJ09[</=U\08U7N'/D$?<E.QRB;A+/
M#1E=R=&3D]C'+L/"%.G!ER!3OHQ>3$&W65679Q-GAY)G(IH',86QG)T0,<$P
M,.7M6V`:<O;E`VHJIB`I!.?*9B1X@@B>W/;#LL5T^UJ!-4K!X8*Z9`SX3!!E
MLCEN9N`@;%Q6;]$+!"Q4VC&[9,HSL<G*L&SXK";@JZZDX279_4)*"VDHF1;I
MKMUB=JB2I`,40$-<='K6C4U'R$B;Z09$B8W=$?;\E*K/4$@$ALRX1D-ZUL"9
M0@IF-5KTZ5$I54XA-HL_6JG7(*=OE=OEBNLU%0[!G*VR=#+%\C"RMAD44"NY
M9\E&QZ#<AUSG$B*)"%Z%*`!EGQ!?>=U95)<4HH2I,@22`.[03(9#''IAZ:7:
M:19F2A("CS;,3):AB>CS1!SU;&/Z&KQOT_(J],K*E[KNYC'$9"W$(9@G98V+
MGZY>2SD8VF4D"/BQTN#%'ZA$3BDH9%,PE[B%$)SPKJ'TZ@<9YU=P:=9E,RF%
M)D9;QC+IB,UFPTNUH60.]+DIRQ]5?H!E"/V];CQSOLDB<$WJ^QHSV'MRF)Z'
ME;$>589DY+6Y8MQJ$3:9.B3*AP.6%OM1&2%)RR4./U+<I'2`G2.;RW39=14%
M\6\PT2FKIW%(6A68Y24A0WI5+`](,+6Y6FJMZ&WU]IAU`4E0RQ&72)XQ)[AR
MY>\I<6F:CKKEEKSMBR5)QZ.;<2IN!.HF4@D:IY(H*3A0K:/O]?:>`DZD1EFA
M?IEQ`P-UD(W6&D:;4M%AV+BV/JU@9<%?)PZLQN/OTY?W;14<BNU2*]8?A&XC
MX#A(C4QPGFO%VXS%5'S;A:Y1%^QED6":6&J6B%<%7:/F+HOWT%T_!>/E(YP4
M[=XT7*1PT=)G15(50ABAF*LHZFWU2Z.K04/MJD1^$;P<P=HRASTU0S5,I?84
M%-*$QZ#Q&V>64?09J$A;)%2$#8X:*L$'+,UX^5A9R-9RT5)Q[H@INF,A'OT7
M#1XR<IF$JB2A#$.4>@@.NE"UM*#K9*7`9I(,C/89C:-\=JDI6"E8!21(@[1N
MZ(22XK=C&VNH>HUY"Z-%X]B5:-M6K5@OF#J=)LVDK7://WV9QXD*\?'R*#I,
M"U-C<W[>&$?OL4SD,4W>F0P.#4MZN"_#^WDJ(74J`6H8%00")=?*)[^N%_:+
M92(U/4\J`4M!12)"4^S+R<Q`ZH>&[A\G[/;V].T.G;[.G3ITZ=-)R&%%,7(G
M@+<1DW-5=L>(.,_CLWB0"6.XR+DLG;LIZ+B,C1$NVGK`N:G123O&]O66J3!F
MZ3=H'^I('U3Q<`3+T$QK98ZNWL4A157"MI7"L]AJ?(1(2.!S.(.&0$05RI7G
MW^9-*P\GE':7*>9F,2,!A+.<SE+&OISM'WS)B*9.!#A5=D,3Q40O-53*'=W%
M,00<88;J@8`^T`Z>/@.IM-PL@Q^V;K_S^F(XT#\__`I/(C]<1ZG)[4=Y\0W7
M>.^`CA;2:,D'#J0=JY4H[)M'-&B0KN7;U=_C%JF@V01(8YSB/:0I!$P@&O4F
MZ6M<@F]70SR'(H]&S..!H'`"304DAP1_W(H]V&87SWR*[X,I;Z,"<>G'TYQ5
MA,&.*6.WBW6)#'FUXEN_5U>.1FX1G$T^2/E2>;-0<RR[EU'D:E5DFB@@`D;E
M+=;W4T=CL;=FK*ZO]I>FHN)25.2F#*>`0G)(D0<%#?%;MC3URN2[@Q34QIF\
M`D@!.(W3E/?GLX0QS!;9]\1%CF_]EGA+)YI2]7#*^,BD\L/O=IP)MO?J&\PP
M?=$"]`^W2Y<N%G3_`/JW<&?&?5VQC%J]DK?Q:*A/3(>\#$V=WO&S5MYG&/9M
MJ$QAK#&WW)TQ5&N1:I4L,LHQ#&6,MRD0R4E(]]6Y&-KE0))0TC+BI&/GYX]L
MN[C7BW>0!$.D19]0N6C4:;FAUUZF2OE45S[Q3>1G,JQ`Q&.8CWU]I176=5%R
M(;<(F`GU0L9;L#D3NC)^M=6L=&M%DI%PAWE>MM-GYFJVF`D4S(OX2Q5Z1<1,
MU$O4C=!(YCY%HHD</ZXG[FM5,/-U#**A@S86D*3+*1QF.F$8^TIEU32Q)0/N
M'P;(<5])GR(!2,C7KCKR3.$1K65%I7*FWU:0=`5)ADB+CDU,@4-EYQP(F2WU
MJ/"6:IEZ!]7&N0*`J.?%0>*FGN]IT:@I0>\:DAR0R23-*CT*P/`PPM#W<)<-
MK?."\4](&6>T#S<8?CTBQ+9#-G/&.I?SB_OA_#H@A.7C`QC3,K\VWJ!<1WV(
M1L%#R3'7&FVZ&>%(HG)5^X9'?QTTT'N(8"F.UD%`3,`=R9NTP#W``Z;&I*IV
META8ZED\KK?(I)W$(F//%)M3**B\7!EX3;6IP$<"N$L-\>U*W[(=V.<]KET!
MRL^Q/>)"'A)APBHB%GI#X"2U$MJ'F$3\Q&Q5-\T<&$`Z%6,H3VD$`=-BNK5Z
MM;-S9.+C8F-ROQA^:04B%I=Z%=NKW*97XJC+B/=CAL(AWGTG&_D<L[=[[L3O
MLT#B[[;ESW3$@/7("[EL)W&45/)0K0JA_,7+CR[NE"CTZ@DREVJ8`!4])7Q2
ML`H[BB],)`8J``N0P"P,/G)SX@PR-$W3VBC-`Z1WC>(QS&WSF9Z>$7M\K.]Z
M+X]]B^;=QIE6Q[M'P84W#T.OVG//9=N@*0]+:I-Q`3.T(ERH>4=D*`C]$P6$
M/9JC:8LRK[>V:'^@4>99W(29DGS`<3%FO%<+=0+J/Z7U4_E'`=0S/`0MCF/9
M#,[+/3!;A7.2$GJFXG<Q(XNW%;A):5,8\\K;<AY>Q_)1-;F'!C"HHXK-=503
M<IF_-DEG9O:<=,2BNZ+QXD,)9`]@IPMIL#*24*!(X3RX`14ZJ@-%I1U3LQ4N
ME"U3S]=,@>,L_E$PB(Y_B''^!5_N#:>TR1,PKF?VR/RA[\;/^R+_`&+=G_\`
M-;V_?R3U/6.+M]Z5/^9=^D8T';?N]C]PCZ(B32RR+9%9RY61;-FR2B[ARX4(
MB@W01(919==502II(HIE$QC&$`*4!$1U'@*5@G$DR^#ICV$C?@<>H9PFSMYP
ME4N?[D]W?[MLU1+FU[#-LM2LFT7;9$.`5)$VVQR\5)Q<I>(<YA\H7T668>VE
M-P3JH@YDH;KU^G``;=?6.Z'TU2VNC/+>:A0?=(SY<#RD;L`B6V2XHS%,WJ2Y
M/5=4.:VM@H1NF01,8[`2L[B4PEWO8VGW_8]NES)M=R0DL>>Q7;'49&3*C<Z"
M-NIKX"R=(NS`IR%`S*TUATV=@!>H)J'.F/WB&`'-9+HQ?;8U<*<]AUO$3G(Y
M*!X@S'5.%M=:!VVURZ9T'LJ(W3&PC@00>$Y9PX1Z3KDD&8A+9QL95GNZ1K:,
MUD_;(ZDG)A5=UU5<\ADO&#,ZQA[C03QP,['(E\?I5WX!T(@0`4/BGIP(=1J*
MD2>[7V71+(C!*CN!ERGJA@Z'O!>:-L?/:`)23YQ^'RP[./\`S:321)('"&%[
M\H\&23.K&229`[CJ1S\A"A[3'.U6*4H=?#J(CKD/6'3`K(]$8AUC*8EEL9#A
MT.2Q3I#%]O0Q99V4P>'@/00UM)G]@G\@>]&<*G]JKW;(T-/2!D\C8'N&6640
M33=;NK`9'O72*8P(XEQ6B<1*8P"7](4>G7V]/#6??%<*.H&I`_\`BI^DJ&KH
M,A%K<YB!]9^B(N:Y(.4C;#QUX2O-RR'DJH2&7B5J6)BO",5.Q\GD*]7-=BJG
M76GZN,5UY*(K82)TSOI1V1%FV;$./>93L3/4M/:9N=]KFV6&EBEYP5N$$)2D
M8G$X3,L!M\\6*[7BBMM,MQQQ/?!)Y4@]J9P&`QECG&2%&1EPR;=48BOP4Y=+
M]>9]8\?7*O$OYVP6"P3KY1P9K$0L8@ZD7[MT]<F[$TDS&'NUJI2V*)CF<6$M
MMMYJ(`Y1+!1.P8>2$8$/U;GU:25*,I[3PZQY91J@\!&Q/)FP+CTJ>-LU,BPN
M7LEWBS9JO53!PFZ6H[FW,X6-@Z?(+H**-CS<37(%J:0*F8Q$7JRJ0";R^X<R
M:[OE-?K\JHHIFB;0&T'XTB2I705$RX2AUZ9MCMKMB67\'E'F(W8``=,A,C8<
M(D?S!?T6/(#_`#3\S?YH2&H[27\S4/[],>J^_<]3^[/X(R!`]@?O:UOMA`G.
M-9;@#231X=MBI$B%(4<:6140*'0!46RE?%E3_P!DHJ<3#^4=91UX2K5E:3\=
M/T$0^--_<C/0O^\5$#_5J_T5<5_.DQ'_`)OY#U/^%7\RJ_RZ_I(B-UC]VH_?
M_H+BRK%FU'".];B7VR;=MP-1;6['EXVCX"25#]&A.5F;;XLKAH6Y4^6,FJK`
MVVN/#`NS=)@/0P"FH51%11(]<J[I66?5%17T*^1]%2YT$<QF%#:#M\V,2;%$
MQ<+(S35"0IM3*>D'E&(.\>0Y'`QFQ<I'&!G#B^S\ZQ=D5)S:<8VE60E<(9G:
M,#MH#)%6;JD,=LY`HG1A[S74G"24O&&-W)*&*LB)VRR2@Z+TQJ>AU+1BHIR$
M5*9!QLF92K:>*3*:3E+#`@@*.^V2HL]04+$Z<^JJ6!'N..T;=A,J^$GF>OO&
M%E4M(OZ\S=-F^3)UNKD^B(&5?R>.Y9T*;4^6,;,CJ`5.79I`7\7C2=J<PT3^
MQTDBIJ*UGHUC4=+[13`(NS8/(KXXSY%<-QV$[IQ[].:C=M3W<U!*J)9D1M!W
M^3RC#=+4$QMDFA9BH-0RGBVVP=\QU?H%A9J=<*T^2D82?@Y)(%FCYBZ2$0$!
M`1*HF8"JHJE,FH4IRF*&:*AAZD?535*2BH02%).!!&?IXC$0XV'VJAI+S*@I
MI0F",O=OW'"%>>,E1)WZD;F?<@GVG1Q[6V93&Z"8"H3>*D%N@AX=JRC0INGM
MZ`&F/J3#0%F`RYU?I15;1_,M:>!_0]$-A?WG^VTLHM\4)\HN%\4Y!SU!SEXX
MGMU>^220QA!QY,M82S27'U8A6A)^S'1I1J_^W#':Z\]%G<'>+.B1Y^Y)ZD7S
MC^7VIWG3=75,4)0Q<J2D1WA/(ZCF4<$]J?=JP.0$]APBM7>FIWJH*=HWGU<@
M',E1`S.$@H8CHVB*L)+;%MH2(=)7T[/)TF)"@L92+W*6!T<2@`CV$4:;GW)5
M##T\2%ZFZ_9JR)N-Q&5]MG]D/^U$1]GT)Q-NJQ_[B_UHJ;Y0H_:OBG$45B_'
M?$EO<VC;F,[3#&N8:M>>,X7Z<92236<A4+6%;IK',%R-;K&Z2E6T8@W<M#-P
M/)`81$Y2D-:--*N=55^U5-THJFVL`J6&VTB6!/:);3R@2)F-T0=Y9H:=H,L4
MC[=8X>R5+69XY<I..[TQ-3;!L`Q)C;!N-Z9F#T]._G+F88"LLD\E92_;=%4A
M&Y7)T4SB:D8J#A<WUAA'PJ;A04&2)6A%4V:20+"=7N.:(N=]JZNN<>I;Y0-T
MI5V$%$Y#+/NSC+&<\XDJ*T4S-,A#]`^JHEVB%+`/P1/[!&R;:S;\BXYJ<]P&
M;U,*0<_:8N-E,FW#<TX>5J@M`=>:2S6-K$;F'5@>1,8JF4ZA$&:ZG9^:F?V#
M7ZZ\W1NF=<3>J-Y00>P&Y%6&0):ECOG$G36Z@+R4_9[Z)&?,5&7G5[\-BIID
M03312#HFB1-),.X3=$TB`0@=QNIC="E#Q$>HZ6!/.0J6!Q!Z3,Q<N4)PV`>;
M=\,9WGJK^/!/!FX^L;Y<<PH-<;;GW1H'*2#%OV-(#/,'&^:,LL"1/+03R75V
M7U0B/BI)1[LXCU6#6@/"W4)JZ%5FJ#]?3XIF<VSL_-.'01"IUM:.XJ1<&1)I
MWUN"MOES^=.%:L69-NV%LE4++N-YMQ7,@8QM\!>:;.-#F(M&V&M23>5C7'4@
ME%1`R[8"*IC]U5$YB&`2F$--&KI6:^G72U("F'$*2H<%"1'3NW12:2H72U"*
MALD*29^3+S]6^-A?8+O#H^_3:3AG=%1#MD&^1:NW/:Z^@X(NM3,AQ`_A=\IK
MSH<ZB:T#8VRY$A4[3+-!16`.U0HCD6^6E^QW5ZV/^LVK`_&2<4GK$NO"'];*
M]NY43=4WFL8C<H9CW;)';$Q2?G%_L@_A#43'OA2_AX(B?GLYTG)>TZB=I(@5
M0INX`(?)SX5D_`>WKYB(=?M`2]--'5@_T39P?BI^A%-L9_U!7#9S*^G'P3U;
M^PG]9J#BOD*H4()YK':D?AC/!V+;N4<T:;?N'&-;?("BGU$E9M+U>*66.(_H
MY9N7P*GX27A1?`R^[87CV'.VW/>!VD^0`]1WQ'ZYM?>M)N38[2>RKHV'?CE\
MW="AG'1O)M&P7>5A#=#73.EX^B6A%ED"#:F$!M6++'TA<A5PR?YBJSJO.55F
MG<`@F_;H*=.I`TV=1V=N_6AZV+P6M',@R]58Q01UX$;B8H=DN*K9<&Z@3Y`H
M!0WI.8ZQETSV0[/GVZ5CFKYD=M6V;'LPUOVQC8-4Z_NLS;.12J<A4<BY/M,;
M$S=!K3A<AOI7R:*<C&QQT#=5")GFDQ`!(;HE*%AS2&D:FX/IY+S7J4P@'!2$
M`GF(W;3/?RPS*AQ%_O35*V>:B93SJED<`9'RI'1SB+$/4@^/#CNS'_TE_>#_
M`/<=#]GY-0?AV9ZLI3O[S^[5'NU9]Q.2RYD?3$94[G^(<?X%7^X-K49RZH23
M'[5'Y0]^-G[9%_L6;/\`^:UM^_DGJ>L<78@72J)R]H=^D8T);<+?3G_T4?1$
M58^H+WE7+`VTR"VNX#![+;L=_EH)MTP[78(ZIK$A7K*JPA\A65BFU[G+=08^
M;;P[=;H7RW$L"Q1_0&$++H.TM5UT^TZP2MM"GO%D^KS#%(XY3ZI;8B=25IIZ
M04;$_:'R4B683AS;1*<P!TSV18GQR[+*IL`V;84VO54C1P[HM92=WRP-4@)^
MMV3;"/XO?;,H<")J+)/)YPHDT\P.]-@@@E[$PZ0-_N[E\O#US<$DK6>1/Q4#
M!*>H8GY4SMB4M="FW42*82*@)JXJ.)^#A"\GJN..9;+N#:EOZQG`'<W_`&\M
M$Z?FEO'-0.[GL(2TB=:-L[DJ"?FN%L:69Z)U#F$PDBY)P<P@1N'2_P#A=J$4
MM<JQU1FQ434C,2<`R$_C`>;C%4UO:!44HN#(FZW@K>1L.6PDCK!.4(=X"SCD
M/;3FG%V?\32YH3(V([E#7>J/@,?R#OXAR"B\7($()?J(:=8&59/41^ZNT<*$
M-X&'3UN-"Q<Z1RAJ0"P\CE4-TTR'1CMV0L*.I<HJE%2W,*2H&?1Z#GORC81V
M3;M,=;Y=KN']T&,'"7ZO90JS:1D88%TUWE0M[$QXVYTN5`AA,E)5>R-7#4W>
M!153(14`[%"B.1;Q:ZBR7)VVU0(<;4<<0%#8H3WC*'Y;ZUNX4:*QO)8F1G(Y
M$>7RC&)2+?Q"_P#].X_^"?4>-G3'L.1C$,MO_>ZV?^*K'_EI]K:-/@P@C/E'
MO1G*IP?4>CWA#A_IYN(W9[R`;(\N9(W!1.6DKQ$;@;)08*S8YS%>L>!'UYC1
M*'+MC-H6%DBU=])-Y*:<&,X=LG)S`)2&ZE(!=)W7^J+K8[VW26\M>S]PE4EM
MI6>::@9J()EA##TG9J&NH%O5(5W@<E,$[ALQ&W:#%"G+QQTW;C5WB6W#4S)6
M&W8WM34MZP=DZQF%S)WG'K]7R0;S,B1%%NYMU.DRJ1LJ!"D`RJ:;@I").$@U
M?M):A8U%:452`E%0@\KJ!*07OD,DJS$574-K=M=<IDS4PHS2K>#MGD=QENZ(
MN5]-)RBX6P;FJ)VG;@<98/J!\J.6E>PSN8B\;4FIW^,NCS_%&>.LGWR.B6<M
M/0ES5.5&-DG:XJMI$Q4%S*)."G0IWB3IJNK:)5UMSKRTMS*V>913(2Q0DDCL
MYF0E+(88V'1]YI67A15*&T.'!*^5((..9XX#'(\#AH?C[?8(#]O7V]?MT@`)
M3RD?=C#4&6V?&*X>8+^BQY`?YI^9O\T)#5CTE_,U#^_3$3??N>I_=G\$9`@>
MP/WM:WA`G.-9G@'_`*'C8I_Z86#^4Z]:REKO^:Z[\M/T$0^--_<C/Y_]XJ(&
M>K5_HJXK^=)B/_-_(>I[PJ_F57^77])$1NL?NU'[_P#07%V_'Y_L&[+?YJN`
M?Y+JSJEW_P"^ZO\`S#GTC$]:ONRG_<I]X1Y.];99@G?S@"V;=]P-:)-U2PI_
M5PDXT*BC::!;6J2I(2[TR5424/%V"&55$2CXI.$#*-URJ(*J$-PL]XKK#6HK
MZ!1#B3(C8I.U)&T'S9C&.=PH:>XTQI:@`H5Y0=XZ//EE&4_R0\<N=^-#<++X
M3S%'JR==D#OI?$>5V#%="J98I";GRVTU%*F%1)A/,$U$TI>*,H9>.=#TZG14
M165U%IO45%J*A%92$(>1@M!S098@[P=AR(X@PD+U9JBT5)9=$VSB@[")^[#8
M<#L)LEX)N;NT<<5^:X*SC)2UFV69$L)5IIK_`(Q)RF"+-++$1<9$IS0!.JI6
M'2HE/8(E$!%5,IG;8HN2'3<US76BF;_3FOH@E%W;3/<'$C$`\?BGJ.!B;TMJ
M1=M=%)4&=&L[<>51VCT;>G-ACB/L=7O7J".8^]TV>B+55[+0*1,U>S5^2:RT
M%.0,[*T"092D7(L55F;YF\;D2.FH0XEZ=0]O72]U4V[3:(M#+Z5(<2M8*2)$
M$%0,Q%OLCC;NH*QQLA3:A,$92)3#;?\`>?[;2OBY1`'=EL2F]S]\B+O%;W]\
M>V<(FJM*R-.VTY>A:'1I,[:4DI(UCEH.3IEB4=V5R61!NHX!<A1;MTB]G4@B
M,[:[XFVLE@T=%4*YBKF=;YEX@"4^8888"69,15=:U5C@=%34L@`"3:^4;=DL
MS/S"(:VKB;LE6K\Q:9_F4Y5JI6JS%24]8Y^:W)49M$Q$)$M%'TE*23][C1%N
MP81S-`ZJJIS`4I"B(CX:EF]4EU:6F[5;5.+,@`R9DG`8<\1[EC*$EQ5?6I2$
MS)+@P`WX0K/Q_;5'G-#R?9IG9[>'O&OVV79M%?58=SY=LEQ[S<485+6NVQ4Y
MKEG7K)X:I%GK!%2MD+Y$819!LW12,(+B*I6;?+J=(Z8I^[I*5%PJSVT)0>ZR
M[84D$$R20/6(Q)RBG6ZWB_7=R;]0:5B4EJ5]9@3RXD88S(E(B4I3AJI#A;,V
M4\]'E-Y;R*]#`!AW81JG@;\[[JN.E"#W?O:6)U@<C;+3_8>A<7/^'MAK:_\`
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MCAZ_XE8JG,O8&9;!W``B1*08*`4?M+T'6NZ:H;JJ9NI:,VW$!0.T@B8)Z008
M0%0TIA]3"_60HC?*1D1U&8,-4>E.Y#_V'[C[/L8R//@UQGN;7_'\4C(.1(RK
M^>X2/!,8EJ*A_*;%R;5F?TW:`=59*.:$#[RH]59XIV#VNWIO-.D^T4^"Y9EM
M6W\TXB>0*CNB\:(NW<U!MSQDTYEP4/3ZI_-$:(I`^^7\A@_A#2`D2)PULL\(
M3KX'+2C=N:GG!M+94JS:5R!9116(("F=)EGRY1J?88/`2=C'[H_:&FUKAHTV
MC[,T09A`\H0)CS]<473;R7KW6N#U25?3^&&K=P^"J'N<P7EG;WDYB$C0\PT2
MPT.QH]@&6;M)U@JV0E60F$H)R<(^%)XT/UZIN4"&#V:5]#6NVZK:KJ<D/-+"
MALR.701@>$XN533MUE,NG<_9+20>&X](.(C&^W,8!O>U+/\`F#;KDUL=G=<,
MWN=I4VH9,4D9).+<":*L++N_C(NRPBK>0:G#J4[=R00$>NM>6RXT]UH&:]A7
MU#J0H':#\7IF"#NA`U]&Y1UBZ-Q/;!(]$OP;92C2J]./L&#95Q]U2Y6^&&.S
M7NL-&9JR!]4B9*2AJJ_CQ+BFF+@IT41"(J+H'ZZ0@4R;^4<%,'4H:SGX@WXW
MF^J;;,Z6E!;3N*@>T3U]GB!/;#ATI;3;[6E;@^O=[1W@?BC\/7'M7J2G0M^'
M+=2`%`X.'6'VH]1Z=@+9CHW4X=`'N$O;[-=?AX/]6TJ1N7US;5'W5A/V$Z!L
M*/IIC*R<_P#RZ_\`@5?[@VM1&$FS@\C\H>_&SELSDHZ'V.;3Y>7?-(N)B=IN
M"I.5E)!RBSCXV-88@J[I\_?.W!TT&K-FU1,HJH<Q2)D*(B(`&L<W,*7=JE"`
M2HU+@`WDK(D-\:!H"$6YDJ(DEA$\<@$C/A"I%'VCSOJ,M\>Y/>[8,WY9P9M"
MVY6!MMVV:V_$;QI#W:S/Z>X/(V*W5^1E6KT(./D#R9I1TX1*FZ54EFK<J@%:
M*!II.7A'A]9:>T(9;>NM0GO7PL32D+P"3+,X<HV"1.V*>FWJU/<':Y;BT4;1
M"6R-LLL#A\HG>H#9$Y'/IF8`XD%IRE\D*```]X.,LH.A,/7P$HD*U[``/L$#
M==0X\1R,!;:(`"0D"//*)#^%/_MO^01Q$KZ8"K3T9(0<]R?\A$W"2[-Q'2\-
M+Y!9245*QSM,R+N/DHY\=PR?,G2)Q(HDJF=,Y!$#%$!Z:YI\25I4EQ-NI0I*
M@01,&>R1`CBO225)*5U3Q2<-FV$CN4+CZO?&GNYNVW*U/7MCJA6[:Y8>R"Z9
M)L0R%B^;5<I0DTL@AU:-YR-=LW$?*()"*:3YJ<2?HCIB+GTM?Z?4EK17-#D<
M]5Q,YE*@,@2!AM'`[X6M]M*[-7*IC,M["=H/6?\`B#%X?I7N20<#;@YG8EE"
M?!KB?<O*&F\3.)%P8C*J9^:,$F_X0B90WE-FF5(&/(T[0``-+,6A0^\N<1H_
MB?IP5M$F]4P*JJG$G,,VACS<2DXGA,Q9M$7@,5!MKJOJU^K/XVP=>7S8T0%O
MXAQ^1NX\/M_B3AT_?T@4DX!68(\\-,G,<(Q#+;_WNMG_`(JL?^6WVMIT_P"Q
M0/DCWHSG4_ME=7O"-%[TC+=5+C8R>X.`>4ZW99`%$0,`B((4'&22G<7_`*OW
MP\/W=9X\55)7J1$IR]F2<I9K61#9T0"+8LG#Z[#CV4Q81S@<:49R3[,K+4ZS
M&-!W$X?))Y)V]3)P31<.[0SCS?C6.7+L_P"9"Y*BVX,C`8032D"-'!AZ(#U@
MM%:C7IR\H></^`=(2Z-G+L5+>F9ZB=\2^HK.F[4!0$_7(!*9><=>!'$",HE^
MQE8&4>Q<FTD8.=A))U'R,>[2<1TO"344[.V>LW*)_*=,).,?MS$.4>U1%4@A
MX&#6I4*14-)4D@M*3F,B,YCJ/6(1J@MAV1P<2?>_!P/7&G/Z>+E>3Y`MLI,/
M9<L2+G=?MPAXN#NIGBJ:<CE#'"0)QM2RPW3,8#NY`"D)'3XE`1))$(X/V@]3
M*&:M?Z6-@N7M5*D_9=024RR0K&:#[Z>L#(PY]+7H76C[IT_XMH2.]0V'B=AZ
MCMBP/F#_`*+#D"Z>/_\`)^9O^6H2.H+2)/\`$E$9&8J$B42=]^YZF7]6?>$9
M`@>P-:W.<(&-:#@/0,VX?-B21C%.)L4RS@!)UZ`5UD2ZNB%'KX]Q"+`!OR@.
MLHZZ,]55I.';3]!$/C3GW*R)B<E_35$`?5KK)%XKH5,ZA"*+;IL2E1(8Y`.J
M8E;R*J<$BB(&4,1,@F$`ZB!0$1\`U/>%1GJ98V^SK/5S(Q&^(W6!!MB"D@CO
MQ]!>6^+N^/SPV';+0'P'_55P%_)=6/\`IU2[Z0;W5RG+VAS9\HQ8+6DBW,)W
M,H^B(EWJ*&&.V/=$*M_.PG`W(OMZL>WW/$,8[%YYDM1KW%(-?USQ;=T6ZJ,7
M<Z@]<)G!)TV$XINFI^K>0:&.@L`E,`EE[)?*W3]<*^B5E+G2?56F>*2-VT',
M'*/!<K93W6E--4IP_%5M2K?Z1MC*9W_;!L]\<NX2PX`SQ#=%T`7EL?9`BV[D
M*;E>BJ.3HQMRJ+Q8![DS@`)/F1Q^IC7@'06#J!3'U+I^_4&H;>FLHE8F7,DR
MYD*&:<,`-HWC*$?=[346BJ+#X[.P[#Q'NSAC3T<R`&W3;R7/<8!0V^T1L4@?
MFB5QD8R@CU'Q#L^F```/#H.ESXO<IM](=[R^&'(/.9SBWZ`/,^]/XGO%,:!O
M]Y_MM(F&A'$V<T\E`SJ]6:,']F1A)16N,I9PJUB7D^FR<'AVLHZ;E.X;1SB0
M!,BZB8"<B0F$`Z@&OJ`V74=[,,\PYB/6EME'%14$*+<N\EA/*>R<)G;[MFGJ
M<.0ZFN<395?[4L689E#BK8,88;RBK5H"VE37*Y:L;M,NF-@MEGC&RJ9!*R4<
MIQZAR%.HW,<`$&[8;SX=6%WVIE%2Y62]9:.8I_)Q`2>,IQ1KK;]57-)94M"6
M)G`$)F.,B9]9(Z\8CYQY</OJ!.,K)=ER-MN-M).E>XB-@<A4:]Y+<6"F72+A
MGB[^'_$&S6MQ<M'2D.X=KBU>,G:"R97"I#=Z:AB#(:AU=H;4M.EFXIJ^=!)2
MM*0")@`RQE(R&!&R/#:-/ZCLSQ=IBURJ`F"009>?#&4B)3AOK938=^MEHMI7
MW^8SV]XVR&ULB"%-9[=K?:;;7I6J#%MCN7T^>TI_41LT28\TA$D554C(=HCT
M-U#2GNS5E9?2+&X^XP4]KO$I209Y"4\)=<7VB7<%-GV]*`N>'*?A/#;$S?+/
M_6CJ)CV1U!,_VE'1C*0@PVQ2WNRL?/6]R%DJM[.\7;`H/$H/C,L79)R=>,B2
M.3U8A2.:=9F=JI6'ZHLIA"2.N":`D<M^Q,@G`_4Q=6ZT-Z*%.VY>'*TU./,A
M"4A`QPDJ<S$%6JU#SE-`&0W/`G/SDC+AU0HA>?2Y<P>2[K;\C7J?VW62[7VS
M3MRM]AD,QRXO9RS663<S$W*NO*QTDB5=_(O%%#`0I2%$W0H```&FW3^)NDZ5
MA%.PFH2RA(2D!L8)`D!Z^,@`)POWM%WQ]U3SI:+BB23S9DF9.6TQP\1Z53EN
MK\K%ST#,;<X2<A)%E+PTU$9OLD;+1$M&N4WD=)Q<BSH*+MA(,'B)%45DCE43
M4*!BB`@`ZYK\4=*NH+3J:A39G,%L2,Q+'M;H^(T3>VU!:"V%C(\V7FABS'%6
M]5-0L4+XVE9_C^R3/(P/X'`Y?O=@L;C),2<C<&K>9?J0M;AZI:)MJ0`.5=_&
M*"LL'>X!81-W+Q]SPQ=JO:$)KT-SGR`#EZ,53EU]$6]I&KVV>Z4:=2Y2YB9G
MRX><'KBL#8UPT<_/'_N-L.YG#%EVF3=TOK:;893A,@94L<W5\GL+%-%LDH2U
M-6-)BGQ9`;"0'K=XU70<-UQ,!3"FHHF>S7O5^AK[;DVRJ35)8;Y>0I0)H*1(
M2[6[`Q#VNPZEME8:MM316J?--6!GPEPAR#:/,[O[!B<SW>W0L)X]S22TS+8D
M'@&T66VT)>GHMXT8*4-(VMLUE4)QVZ4=E<-^ATDR)IB4PB8P`H;FBUMU?):'
M'7*,I!)=2`KFQF,)X91?*15:IB=<E`?^2<#ET[9[=V^0I3Y->"**WU\DFT7=
MBP3KK'%S-=A&;S85X^%C*7*O8N43G<<GAF1&ZWXS(V],OZM2AA.D+>,204`3
M>7TU<--ZW=LFG:JU*YC4&?<'8DJP43YE#C,;8@+OIQ%RNK%:)=T)=Y/;+AMF
M.R=T@89&1:IMTD6Z#=-NV;IIH(-VZ9$D6[=(@)I(H))@4B22*90*4I0`````
M`Z:7TU'M*Q4<3%J&02,`/<(5/Y0=OO/WR#8FR/M9;8*V2X\P%9+VD[_&Z_E^
M;>7ZXU"H6O\`&Z2G*.+$@YCZ^J]4CF3MZ1LT*KYA!1*H5,3`9EZ9N&B;%5M7
M1;M:NO2G+D'*DD$&4I$YX14+U27^Z4ZJ-"6DTY4-N.!!'XQVC<.@0ND?TJO+
M:<IBFJ>`1*<!*8/VWL0\#!T$.H0'AX#IC?[I:6E(>T2_(^&*>G0]W20I);!!
MWB+F,U;-_4WYNV<4O9!*J;4*5B6M4"`Q?99O'>2T:YD#)E$K$6V@X:M7&P_2
MNT6\6>$8HMGZ46W8?B9""#@3D443-3:&\>'%#=UWE":M=0I96D*3-*%$S)`G
MORG.6R+)46_5510)H"II+82$DB0)`RF9XX2W3VSCV;C-V@>HDXP\9S6%,<XA
MV69;P_*6B3NK&F9'S$]CWU;LLV@S0FG-?M-78L'R3*6_#T3JMG:3M(BQ1.EY
M8G4`W5J6\:"U(^FL=76-5:4<LTH$B!,@$$D9G/CP$=MDM^H;0V:?ZM=.53D3
M.60P[2=VT[(<*KIY]S7H%S:&#*-LSB%BU[%'1;H[V,CYY5B@I,,8YXH4BCM@
MTD3*)HJF`#*)E`PAU'2G7R\YY)\DS*><MDQ%U3S<B2J7/+$;CPCY!N4E-R,%
MAZS2>TZEXNOV=$%H8M2K&9K+.5''CYNM+LTI]2:G*XS?R[95I!F75;%32$%'
M!2%,(%$1#U4"+>Y5H1<U.(HIS4IL`J$@92!(&<=%4JJ0R31I2IZ8P49"6T]6
M[">\0GOR>\2?.=RIY#QS?,UTW8E0DL4UR;K--@,:9.N2!$V5CD&$G+K34Y8*
ME+S$PLJZC4113$R3=L'>*:8&54,9MZ9U5HK3%.XQ2JK7"XJ9*TISRF`%`#"*
M%?+#J"]/)==[D<HD)$].V<5L0GI6.7"M34/8Z],;<8.P5Z5CIV!FXK-E@92D
M/-1#Q&0BY6->H8_(LT?Q[YNFLBJ00,FH0#!XAJQN^)^E7VRT\FI4@I*2.[$I
M',>MMVQ#-Z*OC2PXVIH+!G/F^"&@JY*>IGAL.M\>RN-^-VU9":UQ2`)FR6R3
MDEO8G3CZ(S-"S2=3C8!K5'=B3Z@L<2)HLUE@ZBW`HB32T<1X<KK#4(<N"*8J
MF6@A,N@'FF!YXNZ?XH%,6B*;OBF7,9D])Q`)ZNJ%;W/I1>6!XZ<O73G;(NZ>
M.5WCI8V89D#+.72QW#A8P$QX4@"JLH8P@```=?`-,Y/BEI=*0@"IY0)>H/UH
MHZ]#WI:BI1:F?E?!%VO&%L<Y^N+C&%SPQC7'^PG+.,[9<'5_;P.1<N7V.DJY
M;)&-C(F7=Q,_6*@Q76CY5G#-?,;.DE@343$R1B=YP&E:GO>B-3U2:UYRM:JD
MHY9I;204B92""K9,XB+/9+9J*SM*83W"V%*G(DF60P]78-\-UP0S:T+#+V)H
MR8V%6)C59UG%KJNHQG-J,T3RK6-=+D27<L&[X5"(J'*4QTP`1`!'2J<Y`ZKN
MIED*,IYE.R8V$],79)7W0Y_7D)@93X0EOS6>F_SSN;W=/]RVQ*(QHA%YECUY
MW-E,MUO1HS>'RHT500>6VN@>->H/6E_9'!R^3+V&2DT5EAZ_4_=;^B_$2CM=
MJ^SKWWI+1DVI*>::-@.(]7(<)#9%`U#I%VNK?:;?RI"A-0)ECM]/3.($;4>`
M/G<V59UI6XO;W^P*I9*HZSL&:[C,S"0@YR'DVYF<W5K5#'A$D)RM3C,WEN&Q
MS%'N*15,R:R::A)Z[:^T5>J%=NKTU"J9?R)$$9$&>8.(B-M^E;_;:E-52J0E
MU/$><;1TQ>9NNI?J/MWFV?)>VFQ8!X\\:P67:9(8_OMJJ^6KL_LCZN3:)6T\
ME!-Y?\6AH5268F4;B=1-R=$BAA3[3]I@HUI?T%:KFW<4O5SA:7S)2I``GQ(,
MXM%>UJ2MI%4O*P`M,B9_]1A;G_=2N6/_`.U[<?\`30M_^':9'^ZFF!A*I^8/
MUHI/\#7C>W\Z&#MA>"?4:;"-NM1VPU+$G'[E+'&.TYEM07.0<IW9K9:\PG)R
M3LCJ,7DZPWBVTPP0EY=P=$%6Y54TS@GY@E*7HO;]7:#OEP5<EN5[52L@KY4I
M(5(`9'+`#*+A;*;4MNI12286TF<I\23L(VF(D<DW&IZA_E%3HT)GQCLWJV/<
M<R$A-UG&F+\G3$)6#622;&CUK-.K34//2\[--XLYVK8RK@J#5%57RDBF64,:
M8TYJ70>F5+<HDUBGW``5+2DD`8R&(EC(F(Z[V?4UXY4/ED-(,P`92/G,^O\`
M#.RCCOQSZA':S2<'[=\O478[E/!>.'E,HRUSG<HW4F7ZYAZ.D&$>[:13JOPZ
M$':9:I5--1*,!ZV246\I%-94P`)]5S4%1H2Z/O7"C56M5KDU%/*DH4O$XS/9
MF3C*)BV,ZDHV44KW<K83A.9F!U$9;,#NAD\4S=1Z%'IU'I^]]FEZ)RBU1T[#
M_P!:.C$8C.#"<S$`.1[CBP3R7;?);".9HS\.FV`.YG%&4XMFV4N&*+N9J*+2
M>A'"@%.[B'ABD2E8LYRMI-H'8?M4*BLE.Z>U!7Z=KA6T:NP2`M'XJT[B-X_%
M.PX[P8RZVJGNU*JF>ESR)2HC(^CW9RA?GTY'&3O!X]-X>^")W'8NDH"I*8]J
M%)H>5&)FSO'N5%8R\/Y/\6I4B1T9\HV6AQ1<'0<H(.&PJBDH4%"&#5Z\0M26
MS4-KHUT+@+W.5*0?622D`\W7%;TI9:JU53XJ00@@A)V$3&,\CEA+9G(X0X5V
M&\KIT'KW=>G]72HB[QY&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"
M#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!
1!H@@T00:((-$$&B"#1!'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
